Search
forLearn
5 / 801 resultslearn oleanolic acid
learn Tripeptide-1
learn copper tripeptide-1
learn oleic acid
Research
5 / 1000+ resultsresearch Shaping Up Mitochondrion in Motion
Mitochondria change shape to meet energy needs during cell movement.
research Synaptic processes and immune-related pathways implicated in Tourette syndrome
The research suggests that Tourette syndrome is linked to both brain signaling and immune system pathways.
research NF-κB in biology and targeted therapy: new insights and translational implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Stimulation by exosomes from hypoxia-preconditioned hair follicle mesenchymal stem cells facilitates mitophagy by inhibiting the PI3K/AKT/mTOR signaling pathway to alleviate ulcerative colitis
Exosomes from special stem cells help treat ulcerative colitis by reducing inflammation and stress.
research Advances in mitochondria-centered mechanism behind the roles of androgens and androgen receptor in the regulation of glucose and lipid metabolism
Androgens and androgen receptors are important for metabolic health, affecting how the body uses glucose and fats through mitochondrial function.
Community Join
5 / 1000+ resultscommunity AH-001 another topical AR degrader beside GT20029, completed Phase I
AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.
community Treating my DUPA via controlling inflammation
The user has DUPA and suspects autoimmune activity as a cause. They have tried various treatments including finasteride, minoxidil, dutasteride, pyrilutamide, estrogel, hydrocortisone, and clobetasol, and are now seeking a long-term immunosuppressant.
community Setipiprant/PGE2 feedbacks?
community Pp405 phase 2a clinical results
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.